Form 8-K - Current report:
SEC Accession No. 0001193125-21-000942
Filing Date
2021-01-04
Accepted
2021-01-04 16:01:31
Documents
14
Period of Report
2021-01-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d880994d8k.htm   iXBRL 8-K 25248
2 EX-99.1 d880994dex991.htm EX-99.1 10683
6 GRAPHIC g880994g0104215732926.jpg GRAPHIC 5072
  Complete submission text file 0001193125-21-000942.txt   169950

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fstx-20210104.xsd EX-101.SCH 3078
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fstx-20210104_lab.xml EX-101.LAB 18054
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fstx-20210104_pre.xml EX-101.PRE 11386
7 EXTRACTED XBRL INSTANCE DOCUMENT d880994d8k_htm.xml XML 3349
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

EIN.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37718 | Film No.: 21501757
SIC: 2834 Pharmaceutical Preparations